Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: A new paradigm for the treatment of multiple sclerosis

Experimental Biology and Medicine

Volumn 234, Issue 11, 2009, Pages 1383-1392

  Zagon, Ian S ^a   Rahn, Kristen A ^a   Turel, Anthony P ^a   McLaughlin, Patricia J ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

Author keywords

Behavior; Experimental autoimmune encephalomyelitis; Multiple sclerosis; Naltrexone; Neuropathology; Opioids

Indexed keywords

ENDORPHIN; MYELIN OLIGODENDROCYTE GLYCOPROTEIN; NALTREXONE;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; BRAIN INJURY; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PROTEIN EXPRESSION; SCORING SYSTEM;

ANALGESICS, OPIOID; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MICE, INBRED C57BL; MULTIPLE SCLEROSIS; MYELIN-ASSOCIATED GLYCOPROTEIN; NALTREXONE; NERVOUS SYSTEM;

ANIMALIA; MURINAE; MUS;

EID: 70350554076     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0906-RM-189     Document Type: Article

References (57)

1. Forte M, Gold BG, Marracci G, Chaudhary P, Basso E, Johnsen D, Yu X, Fowlkes J, Rahder M, Stem K, Bernardi P, Bourdette D. Cyclophilin C inactivation protects axons in experimental autoimmune encephalomyelitis, an animal model of multiple sclerosis. PNAS 104:7558-7563, 2007. (Pubitemid 47185945)
2. Rizvi SA, Agius MA. Current approved options for treating patients with multiple sclerosis. Neurology 63(12 S6):S8-14, 2004.
3. Fontoura P, Steinman L, Miller A. Emerging therapeutic targets in multiple sclerosis. Curr Opin Neurol 19:260-266, 2006. (Pubitemid 43804680)
4. Lutton JD, Winston R, Rodman TC. Multiple sclerosis: etiological mechanisms and future directions. Exp Biol Med 229:12-20, 2004. (Pubitemid 38101674)
5. Gutstein HB, Akil H. Opioid analgesics. In: The Pharmacological Basis of Therapeutics (10th ed.). New York: McGraw Hill, pp569, 2001.
6. Wang Y, Van Bockstaele EJ, Liu-Chen LY. In vivo trafficking of endogenous opioid receptors. Life Sci 83:693-699, 2008.
7. Wollemann M, Benyhe S. Non-opioid actions of opioid peptides. Life Sci 75:257-270, 2004.
8. Sharp BM. Multiple opioid receptors on immune cells modulate intracellular signaling. Brain Behav Immun 20:9-14, 2006. (Pubitemid 41814658)
9. Zagon IS, McLaughlin PJ. Endogenous opioid systems regulate cell proliferation in the developing rat brain. Brain Res 412:68-72, 1987. (Pubitemid 17096684)
10. Zagon IS, McLaughlin PJ. Endogenous opioids and the growth regulation of a neural tumor. Life Sci 43:1313-1318, 1988. (Pubitemid 18232575)
11. Zagon IS, McLaughlin PJ. Opioid antagonist modulation of murine neuroblastoma: a profile of cell proliferation and opioid peptides and receptors. Brain Res 480:16-28, 1989.
12. Zagon IS, Verderame MF, McLaughlin PJ. The biology of the opioid growth factor receptor (OGFr). Brain Res Brain Res Rev 38:351-376, 2002. (Pubitemid 34219111)
13. Gironi M, Martinelli V, Brambilla E, Furlan R, Panerai AE, Comi G, Sacerdote P. Beta-endorphin concentrations in peripheral blood mononuclear cells of patients with multiple sclerosis: effects of treatment with interferon beta. Arch Neurol 57:1178-1181, 2000. (Pubitemid 30644665)
14. Jankovic BD. Enkephalins and immune inflammatory reactions. Acta Neurol (Napoli) 13:433-441, 1991.
15. Steinman L, Zamvil SS. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol 60:12-21, 2006.
16. Leslie F. Methods used for the study of opioid receptors. Pharmacol Rev 39:197-249, 1987. (Pubitemid 18045485)
17. Blumberg H, Dayton HB. Naloxone, naltrexone, and related noroxymorphones. In: Braude MC, Harris LC, May EL, Smith JP, Villarreal JE, Eds. Narcotic Antagonists. New York: Raven Press, pp33-43, 1973.
18. Sawynok J, Pinsky C, LaBella FS. On the specificity of naloxone as an opiate antagonist. Life Sci 25:1621-1632, 1979.
19. Tempel A, Gardner EL, Zukin RS. Neurochemical and functional correlates of naltrexone-induced opiate receptor up-regulation. J Pharmacol Exp Ther 232:439-444, 1985. (Pubitemid 15162904)
20. Lahti RA, Collins RJ. Chronic naloxone results in prolonged increases in opiate binding sites in brain. Eur J Pharmacol 51:185-186, 1978.
21. Recant L, Voyles NR, Luciano M, Pert CB. Naltrexone reduces weight gain, alters "beta-endorphin", and reduces insulin output from pancreatic islets of genetically obese mice. Peptides 1:309-313, 1980. (Pubitemid 11133483)
22. Zagon IS, McLaughlin PJ. Gene-peptide relationships in the developing rat brain: the response of preproenkephalin mRNA and [Met5]- enkephalin to acute opioid antagonist (naltrexone) exposure. Mol Brain Res 33:111-120, 1995.
23. Misra AL. Current status of preclinical research on disposition, pharmacokinetics, and metabolism of naltrexone. NIDA Res Monogr 28:132-146, 1981.
24. Zagon IS, McLaughlin PJ. Naltrexone modulates tumor response in mice with neuroblastoma. Science 221:671-673, 1983.
25. Zagon IS, McLaughlin PJ. Duration of opioid receptor blockade determines tumorigenic response in mice with neuroblastoma: a role for endogenous opioid systems in cancer. Life Sci 35:409-416, 1984.
26. Zagon IS, McLaughlin PJ. Naloxone prolongs the survival time of mice treated with neuroblastoma. Life Sci 28:1095-1102, 1981. (Pubitemid 11100478)
27. Schulz R, Wuster M, Herz A. Supersensitivity to opioids following the chronic blockade of endorphin action by naloxone. Naunyn Schmied Arch Pharmac 306:93-96, 1979. (Pubitemid 10236247)
28. Tang AH, Collins RJ. Enhanced analgesic effects of morphine after chronic administration of naloxone in the rat. Eur J Pharmacol 47:473-474, 1978.
29. Zukin RS, Sugarman JR, Fitz-Syage ML, Gardner EL, Zukin SR, Gintzler AR. Naltrexone-induced opiate receptor supersensitivity. Brain Res 245:285-292, 1982.
30. Zagon IS, McLaughlin PJ. Stereospecific modulation of tumorigenicity by opioid antagonists. Eur J Pharm 113:115-120, 1985.
31. Zagon IS, McLaughlin PJ. Naloxone modulates body and organ growth of rats: dependency on the duration of opioid receptor blockade and stereospecificity. Pharmacol Biochem Behav 33:325-328, 1989.
32. Suen WE, Bergman CM, Hjelmstrom P, Ruddle NH. A critical role for lymphotoxin in experimental allergic encephalomyelitis. J Exp Med 186:1233-1240, 1997. (Pubitemid 27469018)
33. Encinas JA, Lees MB, Sobel RA, Symonowicz C, Greer JM, Shovlin CL, Weiner HL, Seidman CE, Seidman JG, Kuchroo VK. Genetic analysis of susceptibility to experimental autoimmune encephalomyelitis in a cross between SJL/J and B10.S mice. J Immunol 157:2186-2192, 1996. (Pubitemid 126449699)
34. Milicevic I, Pekovic S, Subasic S, Mostarica-Stojkovic M, Stosic- Grujicic S, Medic-Mijacevic L, Pejanovic V, Rakic L, Stojiljkovic M. Ribavarin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. J Neurosci Res 72:268-278, 2003. (Pubitemid 36389894)
35. Sidman RL. Atlas of the Mouse Brain and Spinal Cord. Cambridge: Harvard University Press, 1979.
36. Tsunoda I, Wada Y, Libbey JE, Cannon TS, Whitby FG, Fujinami RS. Prolonged gray matter disease without demyelination caused by Theiler's murine encephalomyelitis virus with a mutation in VP2 puff B. J Virol 75:7494-7505, 2001. (Pubitemid 32738008)
37. MacNamara KC, Chua MM, Nelson PT, Shen H, Weiss SR. Increased epitope-specific CD8+T cells prevent murine coronavirus spread to the spinal cord and subsequent demyelination. J Virol 79:3370-3381, 2005. (Pubitemid 40327925)
38. Stichel CC, Luebbert H. Inflammatory processes in the aging mouse brain. Neurobiol Aging 28:1507-1521, 2007.
39. Ayers MM, Hazelwood LJ, Catmull DV, Wang D, McKormack Q, Bernard CC, Orian JM. Early glial responses in murine models of multiple sclerosis. Neurochem Int 45:409-419, 2004. (Pubitemid 38625631)
40. Bannerman P, Hahn A, Soulika A, Gallo V, Pleasure D. Astrogliosis in EAE spinal cord: derivation from radial glia, and relationships to oligodendroglia. Glia 55:57-64, 2007. (Pubitemid 44845509)
41. Bannerman P, Hahn A. Enhanced visualization of axonopathology in EAE using thy1-YFP transgenic mice. J Neurol Sci 260:23-32, 2007. (Pubitemid 47225086)
42. Braude MC, Morrison JM. Preclinical toxicity studies of naltrexone. NIDA Res Monogr 9:16-26, 1976.
43. Donahue RN, McLaughlin PJ, Zagon IS. Cell proliferation of human ovarian cancer is regulated by the opioid growth factor-opioid growth factor receptor axis. Am J Physiol Regul Integr Comp Physiol 296: R1716-1725, 2009.
44. Jankovic BD, Maric D. Enkephalins and autoimmunity: differential effect of methionine-enkephalin on experimental allergic encephalomyelitis in Wistar and Lewis rats. J Neurosci Res 18:88-94, 1987. (Pubitemid 18101352)
45. Roy BF, Benkelfat C, Hill JL, Pierce PF, Dauphin MM, Kelly TM, Sunderland T, Weinberger DR, Breslin N. Serum antibody for somatostatin-14 and prodynorphin 209-240 in patients with obsessive- compulsive disorder, schizophrenia, Alzheimer's disease, multiple sclerosis, and advanced HIV infection. Biol Psychiatry 35:335-344, 1994. (Pubitemid 24150269)
46. Akil H, Watson SJ, Young E, Lewis ME, Khachaturian H, Walker JM. Endogenous opioids: biology and function. Annu Rev Neurosci 7:223-255, 1984.
47. Vukusic S, Hutchinson M, Hours M, Moreau T, Cortinovis-Tourniaire P, Adeleine P, Confavreux C, The Pregnancy in Multiple Sclerosis Group. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain 127(Pt 6):1353-1360, 2004. (Pubitemid 38745513)
48. Ziaber J, Baj Z, Pasnik J, Chmielewski H, Tchorzewski H. Increased expression of neutral endopeptidase (NEP) and aminopeptidase N (APN) on peripheral blood mononuclear cells in patients with multiple sclerosis. Immunol Lett 71:127-129, 2000. (Pubitemid 30089776)
49. Ziaber J, Pasnik J, Baj Z, Pokoca L, Chmielewski H, Tchorzewski H. The immunoregulatory abilities of polymorphonuclear neutrophils in the course of multiple sclerosis. Mediators Inflamm 7:335-338, 1998. (Pubitemid 28552766)
50. Wisner A, Dufour E, Messaoudi M, Nejdi A, Marcel A, Ungeheuer MN, Rougeot C. Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways. PNAS 103:17979-17984, 2006. (Pubitemid 44852271)
51. Dass C, Mahalakshmi P. Phosphorylation of enkephalins enhances their proteolytic stability. Life Sci 58:1039-1045, 1996. (Pubitemid 26088527)
52. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p21 pathway to restrict progression of human pancreatic cancer. Mol Cancer 7:5-16, 2008. (Pubitemid 351309035)
53. Cheng F, Zagon IS, Verderame MF, McLaughlin PJ. The opioid growth factor (OGF)-OGF receptor axis uses the p16 pathway to inhibit head and neck cancer. Cancer Res 67:10511-10518, 2007. (Pubitemid 350070827)
54. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. The OGF-OGFr axis utilizes the p16INK4a and p21WAF1/CIP1 pathways to restrict normal cell proliferation. Mol Biol Cell 20:319-327, 2009.
55. Cheng F, McLaughlin PJ, Verderame MF, Zagon IS. Dependence on nuclear localization signals of the opioid growth factor receptor (OGFr) in the regulation of cell proliferation. Exp Biol Med 234:532-541, 2009.
56. Smith JP, Stock H, Bingaman S, Mauger D, Rogosnitzky M, Zagon IS. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol 102:820-828, 2007. (Pubitemid 46496605)
57. Gironi M, Martinelli-Boneschi F, Sacerdote P, Solaro C, Zaffaroni M, Cavarretta R, Moiola L, Bucello S, Radaelli M, Pilato V, Rodegher M, Cursi M, Franchi S, Martinelli V, Nemni R, Comi G, Martino G. A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis. Mult Scler 14:1076-1083, 2008.